Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Non-Current Deffered Revenue (2019 - 2025)

Korro Bio's Non-Current Deffered Revenue history spans 4 years, with the latest figure at $7.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue rose 32.53% year-over-year to $7.8 million, compared with a TTM value of $7.8 million through Dec 2025, up 32.53%, and an annual FY2025 reading of $7.8 million, up 32.53% over the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $7.8 million at Korro Bio, up from $4.8 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $7.8 million in Q4 2025, with the low at $4.5 million in Q2 2025.